The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | First-in-human study of TAK-169 in R/R MM
Shaji Kumar, MD, Mayo Clinic, Rochester, MN, outlines the ongoing, first-in-human, phase I study (NCT04017130) of TAK-169, a dimeric fusion protein of an anti-CD38 antibody single chain variable fragment fused to a modified Shiga-like toxin-A subunit. This study comprises dose escalation and expansion, and will assess the safety and tolerability of TAK-169 in relapsed/refractory multiple myeloma (MM) patients. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
